ASKA Pharmaceutical Holdings Co.,Ltd.
Tokyo Stock ExchangeTotal Valuation
ASKA Pharmaceutical Holdings Co.,Ltd. carries a market capitalization of 74.00B, placing it among publicly traded companies globally. Its enterprise value stands at 56.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 74.00B |
| Enterprise Value | 56.75B |
Share Statistics
ASKA Pharmaceutical Holdings Co.,Ltd. currently has 28.36M shares outstanding.
| Shares Outstanding | 28.36M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
ASKA Pharmaceutical Holdings Co.,Ltd. trades at a trailing price-to-earnings ratio of 18.39. The price-to-sales ratio is 2.01, and the price-to-book ratio stands at 1.05.
| PE Ratio | 18.39 |
| PS Ratio | 2.01 |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.03 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, ASKA Pharmaceutical Holdings Co.,Ltd. trades at an EV/EBITDA multiple of 16.48 and an EV/FCF ratio of 3,893.00. The EV/Sales ratio of 1.82 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.48 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.82 |
| EV / EBITDA | 16.48 |
| EV / EBIT | 16.48 |
| EV / FCF | 3,893.00 |
Financial Position
ASKA Pharmaceutical Holdings Co.,Ltd. maintains a current ratio of 2.82, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.91, indicating elevated leverage, while an interest coverage ratio of 181.26 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.82 |
| Quick Ratio | 0.74 |
| Debt / Equity | 11.91 |
| Debt / EBITDA | 2.22 |
| Interest Coverage | 181.26 |
Financial Efficiency
ASKA Pharmaceutical Holdings Co.,Ltd. posts a return on equity of 5.98 and a return on invested capital of 3.70.
| Return on Equity (ROE) | 5.98 |
| Return on Assets (ROA) | 3.79 |
| Return on Invested Capital (ROIC) | 3.70 |
| Return on Capital Employed (ROCE) | 5.19 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.80 |
Taxes
Over the trailing twelve months, ASKA Pharmaceutical Holdings Co.,Ltd. has paid 1.04B in income taxes, reflecting an effective tax rate of 23.27.
| Income Tax | 1.04B |
| Effective Tax Rate | 23.27 |
Stock Price Statistics
ASKA Pharmaceutical Holdings Co.,Ltd.'s stock has gained approximately 13.40296% over the past 52 weeks. The 50-day moving average sits at 2,787.00, while the 200-day moving average is 2,363.51.
| Beta (5Y) | N/A |
| 52-Week Price Change | 13.40296% |
| 50-Day Moving Average | 2,787.00 |
| 200-Day Moving Average | 2,363.51 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ASKA Pharmaceutical Holdings Co.,Ltd. generated 31.20B in revenue and converted that into 3.42B in net income, yielding earnings per share of 120.62. EBITDA reached 3.44B, while operating income came in at 3.44B.
| Revenue | 31.20B |
| Gross Profit | 15.48B |
| Operating Income | 3.44B |
| Pretax Income | 4.45B |
| Net Income | 3.42B |
| EBITDA | 3.44B |
| EBIT | 3.44B |
| Earnings Per Share (EPS) | 120.62 |
Balance Sheet
ASKA Pharmaceutical Holdings Co.,Ltd. holds 13.71B in cash and equivalents against 7.65B in total debt, resulting in a net debt position of -5.06B. Total book value stands at 59.56B, with working capital of 33.84B providing operational flexibility.
| Cash & Cash Equivalents | 13.71B |
| Total Debt | 7.65B |
| Net Debt | -5.06B |
| Equity (Book Value) | 59.56B |
| Book Value Per Share | 2,103.15 |
| Working Capital | 33.84B |
Margins
ASKA Pharmaceutical Holdings Co.,Ltd. operates with a gross margin of 49.62, reflecting its pricing power and cost economics. The operating margin of 11.04 and net profit margin of 10.95 provide insight into operational efficiency.
| Gross Margin | 49.62 |
| Operating Margin | 11.04 |
| Pretax Margin | 14.27 |
| Profit Margin | 10.95 |
| EBITDA Margin | 11.04 |
Scores
ASKA Pharmaceutical Holdings Co.,Ltd. posts an Altman Z-Score of 3.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.50 |